Eversept Partners LP Sells 70,016 Shares of Evolus, Inc. (NASDAQ:EOLS)

Eversept Partners LP lessened its stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 15.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 383,045 shares of the company's stock after selling 70,016 shares during the quarter. Eversept Partners LP owned approximately 0.60% of Evolus worth $4,229,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in EOLS. KBC Group NV purchased a new stake in Evolus during the 4th quarter valued at $49,000. IFP Advisors Inc boosted its holdings in shares of Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after purchasing an additional 4,709 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Evolus in the fourth quarter worth about $106,000. Quantbot Technologies LP bought a new stake in shares of Evolus in the fourth quarter worth about $118,000. Finally, Tradition Wealth Management LLC increased its holdings in Evolus by 18.2% during the 4th quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock valued at $144,000 after purchasing an additional 2,000 shares during the period. Institutional investors own 90.69% of the company's stock.

Evolus Stock Up 0.9 %

Shares of NASDAQ EOLS traded up $0.10 during mid-day trading on Friday, hitting $11.65. 800,262 shares of the stock traded hands, compared to its average volume of 667,493. The company has a market cap of $740.79 million, a price-to-earnings ratio of -12.80 and a beta of 0.97. The stock has a fifty day moving average price of $12.25 and a 200-day moving average price of $12.90. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on EOLS shares. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research report on Wednesday, April 9th. Barclays lifted their price target on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. BTIG Research began coverage on shares of Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $23.75.

Insider Activity

In other news, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total value of $167,415.12. Following the sale, the director now directly owns 32,183 shares of the company's stock, valued at $418,057.17. The trade was a 28.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider David Moatazedi sold 6,251 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the completion of the sale, the insider now owns 508,619 shares in the company, valued at $6,306,875.60. The trade was a 1.21 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,575 shares of company stock worth $794,369. Corporate insiders own 6.10% of the company's stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.